Home » Stocks » RAPT

Rapt Therapeutics, Inc. (RAPT)

Stock Price: $20.91 USD -0.14 (-0.67%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $20.89 -0.02 (-0.10%) Jan 15, 4:56 PM
Market Cap 513.45M
Revenue (ttm) 3.74M
Net Income (ttm) -53.37M
Shares Out 24.45M
EPS (ttm) -2.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $20.91
Previous Close $21.05
Change ($) -0.14
Change (%) -0.67%
Day's Open 21.05
Day's Range 20.57 - 21.75
Day's Volume 214,410
52-Week Range 11.86 - 48.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, deve...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, deve...

GlobeNewsWire - 2 months ago

-Evidence of Monotherapy and Combination Activity in Charged Tumor Types--Company Advances Several Cohorts into Phase 2 Expansions--Conference Call and Webcast to be Held at 8:30 a.m. ET Today-

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, deve...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, deve...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, deve...

Zacks Investment Research - 4 months ago

RAPT Therapeutics (RAPT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, de...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, de...

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in RAPT Therapeutics.

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, dev...

GlobeNewsWire - 8 months ago

Preclinical and Healthy Volunteer Data Show Promise of RPT193 to Block Th2 Cells in Allergic Inflammatory Disease Preclinical and Healthy Volunteer Data Show Promise of RPT193 to Block Th2 Cel...

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, dev...

GlobeNewsWire - 10 months ago

SOUTH SAN FRANCISCO, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, de...

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...

The Motley Fool - 1 year ago

Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.

Other stocks mentioned: APLT, APRE, BNTX, GKOS, INMD, KRTX, NXTC, PLMR, TPTX

About RAPT

RAPT Therapeutics, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammat... [Read more...]

Industry
Biotechnology
IPO Date
Oct 31, 2019
CEO
Brian Wong
Employees
71
Stock Exchange
NASDAQ
Ticker Symbol
RAPT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for RAPT is 36.17, which is an increase of 72.98% from the latest price.

Price Target
$36.17
(72.98% upside)